Trial Profile
A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms INJOURNEY
- Sponsors Boehringer Ingelheim
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 11 Sep 2017 Results published in the Boehringer Ingelheim Media Release
- 10 Sep 2017 Results published in the American Journal of Respiratory and Critical Care Medicine